1. Home
  2. ANAB

as 04-18-2025 1:30pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Founded: 2005 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 759.5M IPO Year: 2017
Target Price: $36.38 AVG Volume (30 days): 1.0M
Analyst Decision: Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -5.12 EPS Growth: N/A
52 Week Low/High: $12.21 - $41.31 Next Earning Date: 05-08-2025
Revenue: $91,280,000 Revenue Growth: 432.03%
Revenue Growth (this year): -45.77% Revenue Growth (next year): 37.76%

ANAB Daily Stock ML Predictions

Share on Social Networks: